Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy
Public ClinicalTrials.gov record NCT03837327. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy (VOCAL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Venn Biosciences Corporation ("InterVenn") has developed a liquid biopsy that is capable of distinguishing benign from malignant masses in women presenting with adnexal (pelvic) masses, through a simple blood test. The underlying technology combines mass spectrometry and artificial intelligence/machine learning to analyze tumor-associated changes in circulating glycoproteins. The purpose of this study is to prospectively collect de-identified biological samples and data from women with a known pelvic mass, in order to validate ovarian cancer specific glycoproteomic signatures in the blood based on histologically confirmed malignancy status of the mass.
Study identification
- NCT ID
- NCT03837327
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 1,025 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 16, 2019 (Actual)
- Primary completion
- Jan 22, 2024 (Actual)
- Completion
- Jan 22, 2024 (Actual)
- Last update posted
- Apr 23, 2024
2019 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Southern California | Los Angeles | California | 90033 | — |
| Bay Area Gynecology Oncology | San Jose | California | 95128 | — |
| Palo Alto Medical Foundation | Sunnyvale | California | 94086 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| University of South Florida USF Health, OB/Gyn | Tampa | Florida | 33612 | — |
| Memorial Health University Medical Center | Savannah | Georgia | 31404 | — |
| Dr. Sudarshan K. Sharma, Ltd. - Gynecologic Oncology | Hinsdale | Illinois | 60521 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Optimum Clinical Research Group - Southwest Women's Oncology & Health | Albuquerque | New Mexico | 87109 | — |
| Houston Methodist | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03837327, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03837327 live on ClinicalTrials.gov.